Veracyte (VCYT) Receivables (2012 - 2026)

Veracyte has reported Receivables for 15 years, with the latest figure at $54.2 million in Q2 2026.

• Receivables for Q2 2026 came in at $54.2 million, up 6.62% year-over-year; the trailing twelve-month figure through Jun 2026 was $54.2 million (up 6.62% YoY), and the FY2025 annual result was $44.7 million, down 4.01% from the prior year.
• Receivables rose to $54.2 million in Q2 2026, from $50.1 million in the prior quarter.
• Over five years, Receivables peaked at $54.2 million in Q2 2026 and troughed at $39.3 million in Q3 2023.
• A 5-year average of $46.0 million and a median of $46.0 million in 2023 frame the typical range for Receivables.
• The widest annual swing landed in 2022, when Receivables jumped 52.39%; it then dropped 8.28% in 2023.
• A 5-year view of Receivables shows it stood at $44.0 million in 2022, then fell by 8.28% to $40.4 million in 2023, then advanced by 15.22% to $46.5 million in 2024, then decreased by 4.01% to $44.7 million in 2025, then climbed by 21.31% to $54.2 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $54.2 million in Q2 2026, $50.1 million in Q1 2026, and $44.7 million in Q4 2025.